Edison Oncology Holding Corp
EOHC CIK: 0001753347
Company Information
Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
State of Incorporation NV
Business Address 3475 EDISON WAY, MENLO PARK, CA, 94025
Mailing Address 3475 EDISON WAY, MENLO PARK, CA, 94025
Phone (650)690-1927
Fiscal Year End 1231
EIN 831614120
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-1/A IPO registration amendment | January 30, 2026 | View on SEC |
| S-1/A IPO registration amendment | January 16, 2026 | View on SEC |
| S-1/A IPO registration amendment | December 31, 2025 | View on SEC |
| S-1/A IPO registration amendment | December 16, 2025 | View on SEC |
| S-1 IPO registration statement | November 28, 2025 | View on SEC |
IPO Filings
S-1 November 28, 2025
- Developing precision oncology drugs using a 'smart bomb' approach to target tumors without harming healthy cells.
- Experienced leadership team led by CEO Dr. Maria Chen, who previously launched a blockbuster breast cancer drug.
Related Companies
Companies in the same industry (SIC: 2836)
AMGEN INC
AMGN Biological Products, (No Diagnostic Substances)
INTENSITY THERAPEUTICS, INC.
INTS Biological Products, (No Diagnostic Substances)
Vitro Biopharma, Inc.
Biological Products, (No Diagnostic Substances)
Surrozen, Inc./DE
SRZN Biological Products, (No Diagnostic Substances)
Twist Bioscience Corp
TWST Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.